PET / CT With 18F-FDG: Does it Optimize the I 123-MIBG Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-06-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to determine among the patients included a subpopulation that does not need a defibrillator.

This will be done by comparing the number of discordant segments (mismatch) between patients who have a severe arrhythmia (ventricular tachycardia or ventricular fibrillation) with appropriate electrical therapy within 3 years of monitoring and others. "Mismatch" in the definition of this objective is the usual definition: score 3.4 in I123-MIBG (Iodine 123 metaiodobenzylguanidine) and PET at 0,1,2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment Of MRI In Patients With Implanted Cardiac Devices

NCT02815384

Arrhythmias, Cardiac

WITHDRAWN

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

NCT01648296

Heart Failure Obesity Type 2 Diabetes Mellitus +1 more

COMPLETED EARLY_PHASE1

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

NCT03232632

Cardiac Amyloidosis

TERMINATED EARLY_PHASE1

Use of Cardiac MRI in Early Stages of STEMI to Predict Left Ventricular Function Recovery and ICD Implantation

NCT03743935

Acute STEMI Severe Left Ventricular Systolic Dysfunction (Disorder)

TERMINATED NA

Phase Analysis and Obstructive CAD on Rubidium PET

NCT01840696

Coronary Artery Disease

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Defibrillators, Implantable

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The study population

See inclusion and exclusion criteria.

Addional imaging

Intervention Type OTHER

All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Addional imaging

All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with ischemic heart disease with heart failure
* Patients who received myocardial perfusion scintigraphy
* Indication for the implantation of an ICD installed according to current recommendations : LVEF \<30% and NYHA (New York Heart Association) stage II, III.
* The subject must have given his informed consent and signed consent
* The subject must be a member or beneficiary of a social security system

Exclusion Criteria

* Pregnant or lactating women
* History of "open heart" cardiovascular surgery
* Inability to sign informed consent (patient under guardianship)
* Patients with diabetes mellitus
* Patient with proven dementia
* Person refusing to sign the consent
* Someone who already has an ICD at baseline
* Life expectancy less than one year (NYHA IV, other diseases such as neoplastic disease in an advanced stage)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No